Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Energy levels may fluctuate during the early adaptation period
Liraglutide, a once daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)
While much has been published on cellular expression of GPCRs, including the GLP-1R, when evaluating the validity of such data it is key to consider the methodologies applied [e.g., immunohistochemistry (IHC), in situ hybridization (ISH), polymerase chain reaction (PCR), in situ ligand binding (ISBL)]
This ensures researchers can study GLP-1 therapies in populations that reflect real-world diversity, accounting for variations in age, ethnicity, socioeconomic status, and comorbid conditions
US$ 25.34
US$ 23.41
US$ 23.81
US$ 24.24
US$ 22.12
US$ 28.46
US$ 22.57
